 |
|
Description
Substance: Nandrolone Decanoate
Manufacturer: British Dragon Pharmaceuticals
Pack: 10 ampoules (200 mg/ml)
Average Dose: 300-800 mg/week(M) 50-100 mg/week(F)
Half Life: Two Weeks
Water Retention: Yes, some
Aromatization: Low
DHT Conversion: No
Nandrolone decanoate is an injectable anabolic androgenic steroid. It is indicated for the management of the anemia of renal insufficiency and has been shown to increase hemoglobin and red cell mass. Nandrolone cannot be reduced by 5-alpha reductase into DHT and therefore does not have an adverse reaction on the prostate. Instead of DHT, nandrolone metabolizes into dihydronandrolone.
Nandrololone does not
convert into estrogens. Nandrolone binds well to androgen
receptors and also possesses non-receptor mediated stimulation on
muscle growth. Nandrolone decanoate is one of the
most potent anabolic steroid sfor muscle growth with
an excellent myotrophic activity index 3.29–4.92. Nandrolone
up-regulates androgen receptor AR expression in
skeletal muscle, thus potentiating the actions of
other steroids. Nandrolone does not have alkylation on the 17α-carbon
and therefore is not toxic for the liver.
Dosage and administration:
Adult dose is 50-100mg intramuscular injection per week.
Adverse reactions:
Genitourinary System:
In males:
b. postpubertal: Inhibition of testicular function, testicular atrophy and oligospermia, impotence, chronic priapism, epididymitis and bladder irritability. Increased or decreased libido.
In women: Clitoral enlargement, menstrual irregularities.
In both sexes: Increased or decreased libido.
Drug/Laboratory test interactions:
Therapy with nandrolone decanoate may decrease thyroxine-binding
globulin resulting in decreased total T4 serum levels and increased
resin uptake of T3 and T4. Free thyroid hormone levels remain unchanged.
Increased creatine and creatinine excretion, increased serum levels of
creatinine phosphokinase (CPK).
Contraindications:
Male patients with carcinoma of the breast or with known or suspected carcinoma of the prostate. Carcinoma of the breast in females with hypercalcemia: androgenic anabolic steroids may stimulate osteolytic resorption of bones. Pregnancy, because of masculinization of the fetus. Nephrosis or the nephrotic phase of nephritis.
